Lead Product(s): Vectorized Antibodies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: $36.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021
Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team.